Company Profile
Dermata Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Dermata Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Dermata Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Dermata Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Dermata Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
DRMA is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Dermata’s catalysts are SP-104 / acne and dermatology-program updates, where the next clinical step matters most. The company still needs stronger human evidence.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Source: Dermata Therapeutics
- 03
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
Source: Dermata Therapeutics
- 04
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Source: Dermata Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.